US Stock MarketDetailed Quotes
OTLK Outlook Therapeutics
- 1.700
- -3.190-65.24%
Close Nov 27 16:00 ET
- 1.680
- -0.020-1.18%
Post 20:02 ET
40.21MMarket Cap-288P/E (TTM)
2.210High0.870Low62.28MVolume0.981Open4.890Pre Close97.17MTurnover446.73%Turnover RatioLossP/E (Static)23.66MShares12.85052wk High-0.48P/B23.70MFloat Cap0.87052wk Low--Dividend TTM13.94MShs Float219.200Historical High--Div YieldTTM27.40%Amplitude0.870Historical Low1.560Avg Price1Lot Size
About Outlook Therapeutics Company
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Company Profile
SymbolOTLK
Company NameOutlook Therapeutics
Listing DateJun 13, 2016
Founded2010
CEOMr. C. Russell Trenary, III
MarketNASDAQ
Employees24
Fiscal Year Ends09-30
Address111 South Wood Avenue,Unit 100
CityIselin
ProvinceNew Jersey
CountryUnited States of America
Zip Code08830
Phone1-609-619-3990
Company Executives
- Name
- Position
- Salary
- C. Russell Trenary, III
- President, Chief Executive Officer and Director
- 1.76M
- Jeff Evanson
- Chief Commercial Officer
- 718.20K
- Lawrence A. Kenyon
- Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Principal Accounting Officer and Director
- --
- Ralph H. Thurman
- Executive Chairman of the Board
- 242.50K
- Kurt J. Hilzinger
- Independent Director
- 95.00K
- Andong Huang
- Independent Director
- 75.00K
- Dr. Julia A. Haller, M.D.
- Independent Director
- 79.00K
- Faisal G. Sukhtian
- Independent Director
- 113.00K
- Dr. Gerd U. Auffarth, M.D.
- Independent Director
- 79.00K
- Julian S. Gangolli
- Independent Director
- 112.50K
- Yezan Munther Haddadin
- Independent Director
- 110.00K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data